Genetically informed lung cancer medicine

被引：50

作者：

Pao, William ^{[1
]}

Iafrate, A. John ^{[2
]}

Su, Zengliu ^{[1
]}

机构：

[1] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Med,Div Hematol Oncol, Nashville, TN 37232 USA

[2] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA

来源：

JOURNAL OF PATHOLOGY | 2011年 / 223卷 / 02期

关键词：

lung cancer; signal transduction pathway; gene mutation; protein kinase; targeted therapy; genetic analysis; sequencing; gene fusion; gene rearrangement; SMALL-CELL LUNG; RECEPTOR TYROSINE KINASE; EML4-ALK FUSION GENE; C-MET; PHASE-II; ACQUIRED-RESISTANCE; MUTATIONAL ANALYSIS; SOMATIC MUTATIONS; SIGNALING PATHWAY; PIK3CA GENE;

D O I：

10.1002/path.2788

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Knowledge of tumour mutation status has become increasingly important for the prioritization of targeted therapies for cancer. We review here the major known 'driver' mutations with therapeutic relevance in non-small cell lung cancer. We also discuss a variety of methods now being employed in molecular diagnostic laboratories to detect genetic alterations in lung tumours. A genetically-informed approach to lung cancer medicine is rapidly becoming the standard of care worldwide and should lead to improved outcomes for patients. Copyright (C) 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

引用

页码：230 / 240

页数：11

共 109 条

[1]

Ahrendt SA, 2001, CANCER, V92, P1525, DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO

[2]

2-H

[3]

[Anonymous], J CLIN ONCOL

[4]

[Anonymous], J MOL DIAGN IN PRESS

[5]

[Anonymous], J THORAC ONCOL

[6] Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases [J].

Baldus, Stephan E. ;

Schaefer, Karl-L. ;

Engers, Rainer ;

Hartleb, Dinah ;

Stoecklein, Nikolas H. ;

Gabbert, Helmut E. .

CLINICAL CANCER RESEARCH, 2010, 16 (03) :790-799

[7] Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 [J].

Barbie, David A. ;

Tamayo, Pablo ;

Boehm, Jesse S. ;

Kim, So Young ;

Moody, Susan E. ;

Dunn, Ian F. ;

Schinzel, Anna C. ;

Sandy, Peter ;

Meylan, Etienne ;

Scholl, Claudia ;

Froehling, Stefan ;

Chan, Edmond M. ;

Sos, Martin L. ;

Michel, Kathrin ;

Mermel, Craig ;

Silver, Serena J. ;

Weir, Barbara A. ;

Reiling, Jan H. ;

Sheng, Qing ;

Gupta, Piyush B. ;

Wadlow, Raymond C. ;

Le, Hanh ;

Hoersch, Sebastian ;

Wittner, Ben S. ;

Ramaswamy, Sridhar ;

Livingston, David M. ;

Sabatini, David M. ;

Meyerson, Matthew ;

Thomas, Roman K. ;

Lander, Eric S. ;

Mesirov, Jill P. ;

Root, David E. ;

Gilliland, D. Gary ;

Jacks, Tyler ;

Hahn, William C. .

NATURE, 2009, 462 (7269) :108-U122

[8] Mining the Wnt pathway for cancer therapeutics [J].

Barker, Nick ;

Clevers, Hans .

NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (12) :997-1014

[9] Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma [J].

Bean, James ;

Riely, Gregory J. ;

Balak, Marissa ;

Marks, Jenifer L. ;

Ladanyi, Marc ;

Miller, Vincent A. ;

Pao, William .

CLINICAL CANCER RESEARCH, 2008, 14 (22) :7519-7525

[10] MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib [J].

Bean, James ;

Brennan, Cameron ;

Shih, Jin-Yuan ;

Riely, Gregory ;

Viale, Agnes ;

Wang, Lu ;

Chitale, Dhananjay ;

Motoi, Noriko ;

Szoke, Janos ;

Broderick, Stephen ;

Balak, Marissa ;

Chang, Wen-Cheng ;

Yu, Chong-Jen ;

Gazdar, Adi ;

Pass, Harvey ;

Rusch, Valerie ;

Gerald, William ;

Huang, Shiu-Feng ;

Yang, Pan-Chyr ;

Miller, Vincent ;

Ladany, Marc ;

Yang, Chih-Hsin ;

Pao, William .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (52) :20932-20937

← 1 2 3 4 5 6 7 8 9 10 →